Streetbeat News

Price Targets

TYRA

HC Wainwright & Co. analyst Mitchell Kapoor maintains a 'Buy' rating on Tyra Biosciences (NASDAQ:TYRA) and raises the price target from $17 to $20.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:51 am

MCK

Credit Suisse analyst A.J. Rice maintains an Outperform rating on McKesson (NYSE:MCK) and raises the price target from $450 to $485.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 11, 2023 | 11:48 am

CARM

HC Wainwright & Co. analyst Mitchell Kapoor maintains a 'Buy' rating on CARISMA Therapeutics (NASDAQ:CARM) and raises the price target from $10 to $11.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:48 am

SVV

Baird analyst Mark Altschwager maintains an Outperform rating on Savers Value Village (NYSE:SVV) and raises the price target from $27 to $28.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:46 am

EYEN

HC Wainwright & Co. analyst Matthew Caufield has reiterated a 'Buy' rating on Eyenovia (NASDAQ:EYEN) and maintained a $12 price target.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 11:46 am

YETI

Canaccord Genuity analyst Brian McNamara maintains a 'Buy' rating on YETI Holdings and raises the price target from $54 to $58.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 11, 2023 | 11:46 am

DOMA

JMP Securities analyst Matthew Carletti has maintained an 'Outperform' rating on Doma Holdings (NYSE:DOMA), but lowered the price target from $75 to $50.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:44 am

WIX

Benchmark analyst Mark Zgutowicz maintains a Buy rating on Wix.com (NASDAQ:WIX) and raises the price target from $120 to $130.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 11, 2023 | 11:44 am

G

Needham analyst Mayank Tandon maintains a Buy rating on Genpact (NYSE:G) but lowers the price target from $56 to $50.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 11:44 am

ATHA

JMP Securities analyst Jason Butler maintains an 'Outperform' rating on Athira Pharma (NASDAQ:ATHA), but has lowered the price target from $20 to $19.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:43 am